PL376440A1 - Pochodne pirydopirolizyny i pirydoindolizyny - Google Patents

Pochodne pirydopirolizyny i pirydoindolizyny

Info

Publication number: PL376440A1
Authority: PL; Poland
Prior art keywords: pyridopyrrolizine; pyridoindolizine; derivatives; prostaglandin; asthma
Prior art date: 2002-10-30

Application number

PL03376440A

Other languages

English (en)

Inventor

Yves Leblanc

Claude Dufresne

Patrick Roy

Original Assignee

Merck Frosst Canada Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-30

Filing date

2003-10-28

Publication date

2005-12-27

2003-10-28 Application filed by Merck Frosst Canada Ltd. filed Critical Merck Frosst Canada Ltd.

2005-12-27 Publication of PL376440A1 publication Critical patent/PL376440A1/pl

Links

WBDYUBOQSGMRIY-UHFFFAOYSA-N 9h-pyrido[3,2-a]pyrrolizine Chemical compound N1=CC=CC2=C3CC=CN3C=C21 WBDYUBOQSGMRIY-UHFFFAOYSA-N 0.000 title abstract 2
QRGZLKNNVGYPQL-UHFFFAOYSA-N pyrrolo[2,1-f][1,6]naphthyridine Chemical class C12=CC=CN=C2C=CN2C1=CC=C2 QRGZLKNNVGYPQL-UHFFFAOYSA-N 0.000 title abstract 2
206010028735 Nasal congestion Diseases 0.000 abstract 1
229940122144 Prostaglandin receptor antagonist Drugs 0.000 abstract 1
206010039085 Rhinitis allergic Diseases 0.000 abstract 1
201000010105 allergic rhinitis Diseases 0.000 abstract 1
208000006673 asthma Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
150000003180 prostaglandins Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Neurology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Hematology (AREA)
Transplantation (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)

PL03376440A 2002-10-30 2003-10-28 Pochodne pirydopirolizyny i pirydoindolizyny PL376440A1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US42244302P	2002-10-30	2002-10-30
US48262603P	2003-06-26	2003-06-26

Publications (1)

Publication Number	Publication Date
PL376440A1 true PL376440A1 (pl)	2005-12-27

Family

ID=32233493

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL03376440A PL376440A1 (pl)	2002-10-30	2003-10-28	Pochodne pirydopirolizyny i pirydoindolizyny

Country Status (15)

Country	Link
US (1)	US7618979B2 (pl)
EP (1)	EP1558614B1 (pl)
JP (1)	JP4332151B2 (pl)
KR (1)	KR20050084890A (pl)
AT (1)	ATE479686T1 (pl)
AU (1)	AU2003275868B2 (pl)
BR (1)	BR0315681A (pl)
CA (1)	CA2503767C (pl)
DE (1)	DE60334015D1 (pl)
MX (1)	MXPA05004715A (pl)
NO (1)	NO20052591L (pl)
NZ (1)	NZ539406A (pl)
PL (1)	PL376440A1 (pl)
RU (1)	RU2342386C2 (pl)
WO (1)	WO2004039807A1 (pl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7405210B2 (en)	2003-05-21	2008-07-29	Osi Pharmaceuticals, Inc.	Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
NZ543482A (en) *	2003-05-21	2009-02-28	Prosidion Ltd	Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phoshorylase
US7714132B2 (en)	2004-03-11	2010-05-11	Actelion Pharmaceuticals, Ltd.	Tetrahydropyridoindole derivatives
GB0412914D0 (en) *	2004-06-10	2004-07-14	Oxagen Ltd	Compounds
EP1833795B1 (en)	2004-12-23	2009-03-04	Glaxo Group Limited	Pyridine compounds for the treatment of prostaglandin mediated diseases
CA2594280C (en)	2004-12-27	2013-04-23	Anja Fecher	2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
GB0500604D0 (en) *	2005-01-13	2005-02-16	Astrazeneca Ab	Novel process
JP5064219B2 (ja) *	2005-07-22	2012-10-31	塩野義製薬株式会社	Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
EP2397476A3 (en)	2005-07-22	2011-12-28	Shionogi & Co., Ltd.	Indole derivative having PGD2 receptor antagonist activity
EP1932839A4 (en)	2005-09-06	2014-09-10	Shionogi & Co	INDOLECARBOXYLATE ACID DERIVATIVE HAVING ANTAGONIST EFFECT OF THE PGD2 RECEPTOR
ATE530523T1 (de)	2006-08-07	2011-11-15	Actelion Pharmaceuticals Ltd	(3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)- essigsäurederivate
RU2451019C2 (ru) *	2007-10-10	2012-05-20	КЕМИТЕК, ЭлЭлСи	Гетероциклические соединения в качестве антагонистов crth2 рецептора
WO2009099901A1 (en) *	2008-02-01	2009-08-13	Amira Pharmaceuticals, Inc.	N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
BRPI0907364A2 (pt)	2008-02-01	2015-07-14	Amira Pharmaceuticals Inc	Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
WO2009102893A2 (en) *	2008-02-14	2009-08-20	Amira Pharmaceuticals, Inc.	CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors
JP2011513242A (ja) *	2008-02-25	2011-04-28	アミラファーマシューティカルズ，インク．	プロスタグランジンｄ２受容体アンタゴニスト
US8426449B2 (en) *	2008-04-02	2013-04-23	Panmira Pharmaceuticals, Llc	Aminoalkylphenyl antagonists of prostaglandin D2 receptors
US20110112134A1 (en) *	2008-05-16	2011-05-12	Amira Pharmaceuticals, Inc.	Tricyclic Antagonists of Prostaglandin D2 Receptors
WO2010008864A2 (en) *	2008-06-24	2010-01-21	Amira Pharmaceuticals, Inc.	Cycloalkane[b]indole angtagonists of prostaglandin d2 receptors
US8071807B2 (en)	2008-07-03	2011-12-06	Panmira Pharmaceuticals, Llc	Antagonists of prostaglandin D2 receptors
EP2149552A1 (de)	2008-07-30	2010-02-03	Bayer Schering Pharma AG	5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
EP2149551A1 (de)	2008-07-30	2010-02-03	Bayer Schering Pharma AG	N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de)	2008-07-30	2010-02-03	Bayer Schering Pharma Aktiengesellschaft	Indolylamide als Modulatoren des EP2-Rezeptors
US8637671B2 (en) *	2008-09-22	2014-01-28	Merck Canada Inc.	Indole derivatives as CRTH2 receptor antagonists
CA2736571A1 (en) *	2008-09-22	2010-03-25	Merck Frosst Canada Ltd.	Azaindole derivatives as crth2 receptor antagonists
GB2463788B (en) *	2008-09-29	2010-12-15	Amira Pharmaceuticals Inc	Heteroaryl antagonists of prostaglandin D2 receptors
WO2010042652A2 (en)	2008-10-08	2010-04-15	Amira Pharmaceuticals, Inc.	Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
GB2465062B (en) *	2008-11-06	2011-04-13	Amira Pharmaceuticals Inc	Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US8383654B2 (en)	2008-11-17	2013-02-26	Panmira Pharmaceuticals, Llc	Heterocyclic antagonists of prostaglandin D2 receptors
US20100173313A1 (en) *	2009-01-08	2010-07-08	Amira Pharmaceuticals, Inc.	Biomarkers of inflammation
EP2461809A4 (en)	2009-07-31	2013-06-19	Panmira Pharmaceuticals Llc	OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONSITES
US8815917B2 (en) *	2009-08-05	2014-08-26	Panmira Pharmaceuticals, Llc	DP2 antagonist and uses thereof
DE102009049662A1 (de)	2009-10-13	2011-04-14	Bayer Schering Pharma Aktiengesellschaft	2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
EP2521713A4 (en)	2010-01-06	2013-10-02	Panmira Pharmaceuticals Llc	ANTAGONIST OF DP2 AND ITS USES
AR080703A1 (es)	2010-03-22	2012-05-02	Actelion Pharmaceuticals Ltd	Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-carbazol, moduladores de receptores de prostaglandina d2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos alergicos o inmunitarios tales como asma.
RU2633236C2 (ru) *	2011-04-07	2017-10-11	Нексмед Холдингс, Инк.	Способы и композиции для лечения болезни рейно
DK2697223T3 (en)	2011-04-14	2016-09-05	Actelion Pharmaceuticals Ltd	7- (heteroaryl-amino) -6,7,8,9-tetrahydro-pyrido [1,2-a] indole-acetic acid derivatives and their use as prostaglandin D2 receptor
US9351973B2 (en)	2011-09-22	2016-05-31	Merck Sharp & Dohme Corp.	Pyrazolopyridyl compounds as aldosterone synthase inhibitors
EP2757882B1 (en)	2011-09-22	2020-11-04	Merck Sharp & Dohme Corp.	Imidazopyridyl compounds as aldosterone synthase inhibitors
EP2757883B1 (en)	2011-09-22	2021-01-13	Merck Sharp & Dohme Corp.	Triazolopyridyl compounds as aldosterone synthase inhibitors
CA2886117C (en)	2012-10-05	2022-05-31	Merck Sharp & Dohme Corp.	Indoline compounds and their use as aldosterone synthase inhibitors
PE20161177A1 (es)	2014-03-17	2016-11-18	Actelion Pharmaceuticals Ltd	Derivados del acido acetico azaindol y su uso como moduladores del receptor de prostaglandina d2
WO2015140701A1 (en)	2014-03-18	2015-09-24	Actelion Pharmaceuticals Ltd	Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
KR20180053345A (ko)	2015-09-15	2018-05-21	이도르시아 파마슈티컬스 리미티드	결정질 형태

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1241660A (en) *	1984-06-25	1988-09-06	Yvan Guindon	Indole-2-alkanoic acids
US4808608A (en)	1986-01-23	1989-02-28	Merck & Co., Inc.	Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
TW197442B (pl)	1990-02-08	1993-01-01	Pfizer
US5128364A (en)	1991-03-28	1992-07-07	Merck Frosst Canada, Inc.	Pyrrolo[1,2-a]indole hydroxylamine derivatives as inhibitors of leukotriene biosynthesis
DE19510965A1 (de) *	1995-03-24	1996-09-26	Asta Medica Ag	Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung
CN1134411C (zh)	1995-06-21	2004-01-14	盐野义制药株式会社	双环氨基衍生物及含有此类化合物的前列腺素d2拮抗剂
PL191760B1 (pl)	1996-12-13	2006-06-30	Shionogi & Co	Związki, pochodne benzotiofenokarboksyamidu, związki pośrednie, kompozycja farmaceutyczna zawierająca te pochodne oraz lek do leczenia blokady nosa
FR2772763B1 (fr) *	1997-12-24	2004-01-23	Sod Conseils Rech Applic	Nouveaux analogues tetracycliques de camptothecines, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
CN1198649C (zh)	1998-06-03	2005-04-27	盐野义制药株式会社	用于治疗瘙痒的含pgd2受体拮抗剂的药物组合物
AU2002302248B2 (en) *	2001-05-23	2008-03-06	Merck Frosst Canada Ltd.	Dihydropyrrolo[1,2-A]indole and tetrahydropyrido[1,2-A]-indole derivatives as prostaglandin D2 receptor antagonists

2003
- 2003-10-28 WO PCT/CA2003/001658 patent/WO2004039807A1/en not_active Ceased
- 2003-10-28 US US10/532,633 patent/US7618979B2/en not_active Expired - Fee Related
- 2003-10-28 KR KR1020057007434A patent/KR20050084890A/ko not_active Ceased
- 2003-10-28 AT AT03809672T patent/ATE479686T1/de not_active IP Right Cessation
- 2003-10-28 EP EP03809672A patent/EP1558614B1/en not_active Expired - Lifetime
- 2003-10-28 MX MXPA05004715A patent/MXPA05004715A/es unknown
- 2003-10-28 JP JP2005501791A patent/JP4332151B2/ja not_active Expired - Fee Related
- 2003-10-28 NZ NZ539406A patent/NZ539406A/en unknown
- 2003-10-28 PL PL03376440A patent/PL376440A1/pl not_active Application Discontinuation
- 2003-10-28 AU AU2003275868A patent/AU2003275868B2/en not_active Ceased
- 2003-10-28 RU RU2005116254/04A patent/RU2342386C2/ru active
- 2003-10-28 BR BR0315681-8A patent/BR0315681A/pt not_active IP Right Cessation
- 2003-10-28 CA CA002503767A patent/CA2503767C/en not_active Expired - Fee Related
- 2003-10-28 DE DE60334015T patent/DE60334015D1/de not_active Expired - Lifetime
2005
- 2005-05-27 NO NO20052591A patent/NO20052591L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2004039807A1 (en)	2004-05-13
CA2503767C (en)	2009-09-22
RU2005116254A (ru)	2006-01-20
JP2006506457A (ja)	2006-02-23
EP1558614A1 (en)	2005-08-03
JP4332151B2 (ja)	2009-09-16
BR0315681A (pt)	2005-09-06
US7618979B2 (en)	2009-11-17
AU2003275868A1 (en)	2004-05-25
DE60334015D1 (de)	2010-10-14
AU2003275868B2 (en)	2009-07-09
NO20052591L (no)	2005-07-29
US20050272756A1 (en)	2005-12-08
NO20052591D0 (no)	2005-05-27
NZ539406A (en)	2007-05-31
RU2342386C2 (ru)	2008-12-27
CA2503767A1 (en)	2004-05-13
MXPA05004715A (es)	2005-08-03
ATE479686T1 (de)	2010-09-15
EP1558614B1 (en)	2010-09-01
KR20050084890A (ko)	2005-08-29

Legal Events

Date	Code	Title	Description
2011-05-31	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
PL376440A1 (pl)	2005-12-27	Pochodne pirydopirolizyny i pirydoindolizyny
DE60215000D1 (de)	2006-11-09	DIHYDROPYRROLOi1,2-AöINDOL- UND TETRAHYDROPYRIDOi1,2-AöINDOLDERIVATE ALS PROSTAGLANDIN REZEPTOR ANTAGONISTEN
BR0112756A (pt)	2003-06-24	Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
MXPA03010134A (es)	2004-03-10	Derivados de ciclohexan-1-4-diamina sustituidos.
AU2003272285A1 (en)	2004-03-29	Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
GB0504828D0 (en)	2005-04-13	Therapeutic agents
MY132566A (en)	2007-10-31	Benzimidazolone histamine h3 antagonists
ATE399770T1 (de)	2008-07-15	Tachykininrezeptorantagonisten
AU2003242544A1 (en)	2003-12-12	New indolylpiperidine derivatives as potent antihistaminic and antiallergic agents
WO2001079169A3 (en)	2002-04-04	Prostaglandin d2 receptor antagonists
UA74419C2 (uk)	2005-12-15	Заміщені піридини та їх застосування як антагоністів рецептору метаботропного глутамату
WO2002072570A3 (en)	2003-03-06	Non-imidazole compounds as histamine h3 antagonists
MX2007000036A (es)	2007-05-18	Antagonistas del receptor 2 de citocina quimioatrayente de sales cuaternarias.
WO2003006604A3 (en)	2003-10-02	Cyclic peptides as potent and selective melanocortin-4 receptor agonists
NO20070588L (no)	2007-03-23	Piperidinderivater som NK1-antagonister.
GB0426313D0 (en)	2005-01-05	Therapeutic agents
WO2004066960A3 (en)	2004-10-21	Combination of h1, h3 and h4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
AU2003258630A1 (en)	2004-03-11	Pyrimidine derivatives as selective cox-2 inhibitors
WO2005048932A3 (en)	2006-09-14	N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity
WO2006114666A8 (en)	2008-04-03	SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES
GT200200003A (es)	2002-08-19	Antagonistas de receptores de histamina
AU2002254930A1 (en)	2002-10-03	Novel medicament compositions based on anticholinergic agents and endothelin antagonists
WO2005094798A3 (en)	2006-04-13	Pharmaceutical compositions based on anticholinergics and ccr2 receptor antagonists
AU2003259759A1 (en)	2004-02-25	Gal3 receptor antagonists for the treatment of affective disorders
WO2004024682A3 (en)	2004-07-08	N-ureidoalkyl-piperidines as modulators of chemokine receptor activity.